Open Clinical Studies

Adults 18 and over who tested positive for COVID-19 (not more than 10 days ago) and are at home.

In addition, you must have at least 1 of the symptoms below within the last 24 hours: fever, sore throat, chills, body pain or muscle aches, headache, tiredness, trouble breathing or cough

Please visit https://www.riseabovecovid.org for more information

OUTPATIENT TREATMENT FOR RECENT COVID INFECTION (ACTIV-2)

Phase 2/3 platform trial of treatments for outpatients with newly diagnosed COVID. Currently providing a single infusion of monoclonal antibodies vs. placebo for people with a diagnosis of COVID and symptom onset of less than 8 days. Includes multiple additional agents including oral therapy, inhaled interferon, IM monoclonal antibody, subQ monoclonal antibody, and bovine serum albumin.

Safe transportation will be provided for patients during the isolation time period.

DORAVIRINE FOR PEOPLE WITH EXCESSIVE WEIGHT GAIN ON INTEGRASE INHIBITORS AND TENOFOVIR ALAFENAMIDE

Phase 4, three arm, open label randomized study randomizing people living with HIV to stay on current INSTI based ART vs change to the NNRTI doravirine with Truvada (TDF/FTC) vs doravirine with Descovy (TAF/FTC) for 48 weeks.

OBSERVATIONAL STUDY FOR PEOPLE WITH PERSISTENT LOW LEVEL VIREMIA DESPITE EFFECTIVE ART

Enrollees in this observational study will undergo a number of observational assessments including questionnaires, neuropsychiatric testing, and evaluation of blood, hair, and spinal fluid. ​​​​​​

INJECTABLE CABOTEGRAVIR+RILPIVIRINE FOR INDIVIDUALS WHO HAVE BEEN NON-ADHERENT TO ORAL ART

Phase III study. All participants will receive oral ART x 24 weeks with conditional economic incentives to attain HIV suppression. Those who are suppressed at 24 weeks will be randomized to IM CAB+RIL every 4 weeks (after an oral lead-in) vs continued oral ART for 48 weeks.

ONE MONTH OF LATENT TB TREATMENT WITH INH/RIFAPENTINE FOR HIV+ INDIVIDUALS TAKING DOLUTEGRAVIR

This is a drug interaction study which will evaluate the pharmacokinetics of dolutegravir during one month of LTBI treatment with INH/Rifapentine. An additional 50 mg dose will be given daily in the first phase of the study. Participants will have two separate days (day 0 and day 28) with intensive PK evaluations, conducted in a clinical research center

RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE ANTI-INFLAMMATORY EFFICACY OF LETERMOVIR (PREVYMIS) IN ADULTS WITH HIV-1 AND ASYMPTOMATIC CMV 

This is a phase 2, randomized, open-label, placebo-controlled, multicenter trial to evaluate the anti-inflammatory efficacy of letermovir, administered once daily for 48 weeks in adults with HIV and asymptomatic CMV, who are on ART-mediated suppression. Participants will be randomized 1:1 to receive either letermovir or placebo. A futility analysis will be performed after the first 40 participants, who have started study treatment, reach their 8-week study visit.

SAFETY, TOLERABILITY, AND EFFICACY OF IL-15 SUPERAGONIST (N-803) WITH AND WITHOUT COMBINATION BROADLY NEUTRALIZING ANTIBODIES TO INDUCE HIV-1 CONTROL DURING ANALYTIC TREATMENT INTERRUPTION

Participants will undergo leukapheresis, and a subset will also undergo optional rectal biopsy and/or lymph node fine needle aspirations (FNAs) (Step 1).

Participants will be randomized to either the N-803 only arm (Arm A) or the N-803 with combination bNAbs arm (Arm B) and will be followed for ~100 weeks.

DoxyPEP

Eligible individuals must be a man who has sex with men or a transgender woman, living with HIV or taking/starting HIV PrEP, with a history of gonorrhea, chlamydia or syphilis in the past year.

For more information, visit: https://depts.washington/edu/doxypepstudy

DoxyPEP

Phase IV study of doxycycline taken as a single 200 mg dose within 24-72 hours after condomless sexual contact. Participants will be randomized 2:1 to receive open label doxycycline or continued standard of care for 12 months of follow-up.

Contact (415) 939-4543 (living with HIV, enrolled at ZSFG)

or (415) 855-0402 (PrEP patients, enrolled at SF city clinic)

ACTG 5380

ACUTE HCV TREATMENT WITH 4 WEEKS of GLECAPREVIR/PIBRENTASVIR (HIV+ or HIV UNINFECTED)

Individuals with acute HCV will receive open label G/P x 4 weeks.  Those who fail to attain an SVR12 will have the option to take study-provided retreatment.

ACTG 5379

HBV VACCINATION FOR PRIOR HBV VACCINE NON-RESPONDERS WHO ARE LIVING WITH HIV

Participants will be randomized 1:1 to receive HBV vaccination with HEPLISAV-B or Energix-B, and response to vaccination will be evaluated ​​​​​​.